New biotech investment firm seeks to ‘free the founders’; reports of Seagen CEO’s arrest raise questions on biotech’s response

Biotech veteran Alexis Borisy and entrepreneur Zach Weinberg are homing in on independent founders, rather than starting biotechs themselves. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by         STAT+: A new biotech investment firm, headed by a pair of noteworthy VCs, seeks to 'free the founders' By Allison DeAngelis Adobe Biotech veteran Alexis Borisy and entrepreneur Zach Weinberg are homing in on independent founders, rather than starting biotechs themselves. Read More STAT+: Police reports detailing Seagen CEO's arrest raise questions about biotech's response By Damian Garde Getty Images for Gabrielle's Angel Foundation Seagen, the $22 billion company Siegall co-founded in 1997, said he had taken a leave of absence sixteen days after the incident. Read More In radical claim, study suggests inflammation wards off chronic pain instead of causing it By Jason Mast Adobe The study repudiates much of what pain researchers believe about how acute pain can develop into a chronic and debilitating condition. Read More Sponsor content by Legend Biotech Commercializing cell therapy: launching "disruptive" technologies requires innovative strategies Personalized medicine is changing the therapeutic landscape for patients and providers, but creating "disruptive" and highly individualized therapies requires a new approach to commercialization. Steve Gavel, vice president of global commercial development at Legend Biotech, details how Legend, which was incorporated less than a decade ago, created the infrastructure to bring cell therapies to market at an accelerated speed. Read about its approach to commercialization and how it hopes a three-pronged strategy can ensure success. Transfusion of brain fluid from young mice is a memory-elevating elixir for old animals By Megan Molteni Luis de la Torre-Ubieta/Geschwind Laboratory/UCLA/Wellcome The tantalizing research suggests youthful factors circulating in the cerebrospinal fluid might be tapped to slow cognitive declines. Read More STAT+: As problems emerge in medical AI models, research points to a new way to strip them of bias By Katie Palmer Adobe AI researchers argue for a more routine and robust way of analyzing how well algorithms perform in a new paper. Read More U.S. overdose deaths hit record 107,000 in 2021, CDC says By Mike Stobbe — Associated Press Lisa Rathke/AP The provisional 2021 total translates to roughly one U.S. overdose death every 5 minutes, and marked a 15% increase from the previous record. Read More STAT+: Roche anti-TIGIT cancer immunotherapy fails second clinical trial, raising doubts about drug class By Adam Feuerstein SEBASTIEN BOZON/AFP via Getty Images The outcome is a significant blow to the Swiss pharma giant’s effort to develop the most important cancer drug in its research pipeline. Read More Opinion: Listen: Get sick, go to the doctor, incur debt, repeat By Patrick Skerrett Health care makes an alarming of number of Americans sicker, at least financially, by generating medical debt. Preventing it is key. Read More Wednesday, May 11, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser